title: Serelaxin in clinical development: past, present and future.
abstract: The availability of highly purified recombinant human relaxin, serelaxin, has allowed clinical trials to be conducted in several indications and the elucidation of its pharmacology in human subjects. These studies have demonstrated that serelaxin has unique haemodynamic properties that are likely to contribute to organ protection and long-term outcome benefits in acute heart failure. Clinical observations support its consideration for therapeutic use in other patient populations, including those with chronic heart failure, coronary artery disease, portal hypertension and acute renal failure.
  
  
  
  This article is part of a themed section on Recent Progress in the Understanding of Relaxin Family Peptides and their Receptors. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v174.10/issuetoc.
authors.affiliation: Oakland, CA, USA.
authors.forename: Elaine
authors.initials: E
authors.lastname: Unemori
mesh_terms: D002986:Clinical Trials as Topic; D006333:Heart Failure / Q000188:drug therapy* / Q000378:metabolism; D006801:Humans; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D012065:Relaxin / Q000008:administration & dosage / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use*
chemical_list: D011994:Recombinant Proteins; C577649:serelaxin protein, human; D012065:Relaxin